10 20 30 40 50 60 70 80 1EFF - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER HYDROLASE/HYDROLASE INHIBITOR 08-FEB-00 1EFF
TITLE KNOWLEDGE BASED MODEL OF AN INHIBITOR BOUND TO A TITLE 2 THIOL(CYSTEIN) PROTEASE, PAPAIN COMPLEXED WITH NAPQI
CAVEAT 1EFF THREE RESIDUES HAVE INCORRECT CHIRALITY
COMPND MOL_ID: 1; COMPND 2 MOLECULE: PAPAIN; COMPND 3 CHAIN: A; COMPND 4 EC: 3.4.22.2
SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: CARICA PAPAYA; SOURCE 3 ORGANISM_COMMON: PAPAYA; SOURCE 4 ORGAN: FRUIT; SOURCE 5 SECRETION: LATEX
KEYWDS CYSTEIN (THIOL) PROTEASE INHIBITOR/ADDUCT, NAPQI(N-ACETYL-P- KEYWDS 2 BENZOQUINONE IMINE), A REACTIVE METABOLITE OF ACETAMINOPHEN KEYWDS 3 (NSAID), PROTEIN-INHIBITOR COMPLEX, NSAID.
EXPDTA THEORETICAL MODEL
AUTHOR A.BANERJEE,A.K.PAL,S.BHATTACHARYYA
REVDAT 2 26-SEP-01 1EFF 3 ATOM CONECT REVDAT 1 15-MAR-00 1EFF 0
JRNL AUTH A.BANERJEE,A.K.PAL,S.CHAKRABORTY,S.GHOSH, JRNL AUTH 2 S.BHATTACHARYYA JRNL TITL STRUCTURAL BASIS OF INACTIVATION OF THIOL PROTEASE JRNL TITL 2 BY IMINE (NAPQI). A KNOWLEDGE BASED MOLECULAR JRNL TITL 3 MODELLING STUDY OF THE ADDUCT OF NAPQI WITH THE JRNL TITL 4 THIOL PROTEASE OF PAPAIN FAMILY. JRNL REF TO BE PUBLISHED JRNL REFN
REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH W.CHEN,J.P.SHOCKCOR,R.TONGE,A.HUNTER,C.GARTNER, REMARK 1 AUTH 2 NELSON S.D. REMARK 1 TITL PROTEIN AND NONPROTEIN CYSTEINYL MODIFICATION BY REMARK 1 TITL 2 N-ACETYL-P-BENZOQUINONE IMINE VIA A NOVEL IPSO REMARK 1 TITL 3 ADDUCT REMARK 1 REF BIOCHEMISTRY V. 38 8159 1999 REMARK 1 REFN ASTM BICHAW US ISSN 0006-2960 REMARK 1 REFERENCE 2 REMARK 1 AUTH D.YAMAMOTO,K.MATSUMOTO,H.OHISHI,T.ISHIDA,M.INOUE, REMARK 1 AUTH 2 K.KITAMURA,H.MIZUNO REMARK 1 TITL REFINED X-RAY STRUCTURE OF PAPAIN(DOT)E-64-C REMARK 1 TITL 2 COMPLEX AT 2.1-ANGSTROMS RESOLUTION REMARK 1 REF J.BIOL.CHEM. V. 266 14771 1991 REMARK 1 REFN ASTM JBCHA3 US ISSN 0021-9258 REMARK 1 REFERENCE 3 REMARK 1 AUTH D.YAMAMOTO,K.MATSUMOTO,H.OHISHI,T.ISHIDA,M.INOUE, REMARK 1 AUTH 2 K.KITAMURA,H.MIZUNO REMARK 1 TITL THE IMPORTANCE OF VAL-157 HYDROPHOBIC INTERACTION REMARK 1 TITL 2 FOR PAPAIN INHIBITORY ACTIVITY OF AN EPOXYSUCCINYL REMARK 1 TITL 3 AMINO ACID DERIVATIVE; A STRUCTURE-ACTIVITY REMARK 1 TITL 4 RELATIONSHIP BASED ON THE CRYSTAL STRUCTURE OF THE REMARK 1 TITL 5 PAPAIN-E-64-C COMPLEX REMARK 1 REF FEBS LETT. V. 253 134 1990 REMARK 1 REFN ASTM FEBLAL NE ISSN 0014-5793 REMARK 1 REFERENCE 4 REMARK 1 AUTH K.MATSUMOTO,D.YAMAMOTO,H.OHISHI,K.TOMOO,T.ISHIDA, REMARK 1 AUTH 2 M.INOUE,T.SADATOME,K.KITAMURA,H.MIZUNO REMARK 1 TITL MODE OF BINDING OF E-64-C, A POTENT THIOL PROTEASE REMARK 1 TITL 2 INHIBITOR, TO PAPAIN AS DETERMINED BY X-RAY REMARK 1 TITL 3 CRYSTAL ANALYSIS OF THE COMPLEX REMARK 1 REF FEBS LETT. V. 245 171 1989 REMARK 1 REFN ASTM FEBLAL NE ISSN 0014-5793 REMARK 1 REFERENCE 5 REMARK 1 AUTH M.-J.KIM,D.YAMAMOTO,K.MATSUMOTO,M.INOUE,T.ISHIDA, REMARK 1 AUTH 2 H.MIZUNO,S.SUMIYA,K.KITAMURA REMARK 1 TITL CRYSTAL STRUCTURE OF PAPAIN-E64-C COMPLEX. BINDING REMARK 1 TITL 2 DIVERSITY OF E64-C TO PAPAIN S=2= AND S=3= SUBSITES REMARK 1 REF BIOCHEM.J. V. 287 797 1992 REMARK 1 REFN ASTM BIJOAK UK ISSN 0306-3275
REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : NULL REMARK 3 AUTHORS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4 REMARK 4 1EFF COMPLIES WITH FORMAT V. 2.3, 09-JULY-1998
REMARK 5 REMARK 5 RECENTLY POTENTIAL CYSTEIN PROTEASE INHIBITORS/ADDUCTS ARE REMARK 5 IN THE FOCUS FOR THEIR IMPORTANT APPLICATION IN MEDICAL REMARK 5 AND INDUSTRIAL SECTORS. A CLASS OF DRUGS WITH EXCELLENT REMARK 5 MECHANISM FOR FIGHTING DISEASES HAS BREATHED HOPE INTO REMARK 5 MEDICAL RESEARCH. THESE DRUGS,PROTEASE INHIBITORS, ARE REMARK 5 BEING USED AGAINST EVERYTHING FROM INFECTION, COMMON COLD, REMARK 5 INFLAMMATIONS IN ARTHRITIS TO AIDS AND EVEN IN CANCER. REMARK 5 IN ABSENCE OF ANY EXPERIMENTAL STRUCTURAL DATA FOR REMARK 5 N-ACETYL-P-BENZOQUINONE IMINE, A REACTIVE METABOLITE OF REMARK 5 ACETAMINOPHEN, COMPLEXED WITH PAPAIN, MOLECULAR MODELLING REMARK 5 CAN BE USED TO IDENTIFY CONSERVED SIGNATURES OF BIOLOGICALLY REMARK 5 IMPORTANT CONFORMATIONS AND MOTIFFS, RELEVANT IN BIOLOGICAL REMARK 5 FUNCTIONS.
REMARK 6 REMARK 6 N-ACETYL-P-BENZOQUINONE IMINE (NAPQI), A REACTIVE METABOLITE REMARK 6 OF ACETAMINOPHEN, IS A QUINONE IMINE THAT IS FORMED BY REMARK 6 CYTOCHROME P450 OXIDATION OF ACETAMINOPHEN (APAP), A WIDELY REMARK 6 USED ANALGESIC AND ANTIPYRETIC DRUG. NAPQI IS HIGHLY REMARK 6 REACTIVE AND THERE IS SUBSTANTIAL EVIDENCE THAT IT REMARK 6 IS RESPONSIBLE FOR FOR FORMING EVENTS THAT LEAD REMARK 6 TO HEPATOTOXICITY IN HUMANS WHEN LARGE DOSES REMARK 6 OF ACETAMINOPHEN ARE TAKEN. NAPQI IS AN ELECTROFILE REMARK 6 THAT CAN FORM COVALENT ADDUCTS WITH NUCLEOPHILES REMARK 6 SUCH AS GLUTATHIONE (GSH) AND PROTEIN THIOLS. REMARK 6 THE COVALENT BINDING OF PROTEIN THIOLS BY NAPQI REMARK 6 HAS BEEN IMPLICATED IN THE PATHOGENESIS OF HEPATOTOXICITY REMARK 6 CAUSED BY ACETAMINOPHEN.
REMARK 7 REMARK 7 CLINICALLY POTENTIAL INHIBITOR, REACTIVE METABOLITE OF REMARK 7 ACETANILIDE, ACETAMINOPHEN ETC HAS BEEN MODELLED REMARK 7 AGAINST HIGH RESOLUTION(1.9 A) X-RAY STRUCTURE REMARK 7 PAPAIN-E64-C (PDB CODE 1PPP). THE INHIBITOR IN THE PRESENT REMARK 7 STUDY IS A SMALL MOLECULE CONSISTING OF 12 ATOMS WITH ONE REMARK 7 CARBONYL OXYGEN. THE INHIBITOR HAS BEEN MODELLED IN THE REMARK 7 COMPLEXED STATE BY DOCKING THE INHIBITOR TO PAPAIN AND REMARK 7 SUBSEQUENT ENERGY MINIMIZATION OF THE COMPLEX. REMARK 7
REMARK 8 REMARK 8 DIFFERENCE ACCESSIBLE SURFACE AREA (DASA) STUDY OF PAPAIN REMARK 8 WITH AND WITHOUT THE INHIBITOR (N-ACETYL-P-BENZOQUINONE REMARK 8 IMINE) SHOW THAT THE RESIDUES AT THE ACTIVE SITE OF PAPAIN, REMARK 8 GLYCINE (GLY66), CYSTEIN (CYS25) AND ALANINE (ALA160) REMARK 8 INTERACT WITH THE INHIBITOR. DASA STUDY SUGGESTS REMARK 8 HOW BINDING AFFINITY AND MOLECULAR RECOGNITION AFFECT REMARK 8 STRUCTURE-FUNCTION ACTIVITY OF THE SYSTEM. REMARK 8
REMARK 9 REMARK 9 MOLECULAR CONFORMATION OF THE INHIBITOR REMARK 9 (N-ACETYL-P-BENZOQUINONE IMINE) FALL IN THE ALLOWED REGION REMARK 9 OF STEREOCHEMISTRY AND ALL THE CONFORMATIONS OF PAPAIN REMARK 9 EITHER FALL ALLOWED REGION OR IN THE EXTENDED ALLOWED REGION REMARK 9 OF THE RAMACHANDRAN PLOT SIGNIFYING THAT THE COMPLEX REMARK 9 IS OF THE CORRECT AND SIMILAR CONFORMATION AS THAT REMARK 9 OF REPORTED OTHER PAPAIN-INHIBITOR COMPLEX.
REMARK 10 REMARK 10 MODEL BUILDING OF THE INHIBITOR IN THE COMPLEXED STATE WAS REMARK 10 PERFORMED ON A SILICON GRAPHICS INDIGO WORKSTATION USING REMARK 10 THE COMMERCIAL SOFTWARE PACKAGE INSIGHT-II REMARK 10 (BIOSYM TECHNOLOGY, SAN DIEGO, CA).
REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 15-FEB-2000. REMARK 100 THE RCSB ID CODE IS RCSB010525.
REMARK 220 REMARK 220 EXPERIMENTAL DETAILS REMARK 220 EXPERIMENT TYPE : THEORETICAL MODELLING REMARK 220 REMARK 220 REMARK: NULL
REMARK 225 REMARK 225 THEORETICAL MODEL REMARK 225 THE COORDINATES IN THIS ENTRY REPRESENT A MODEL STRUCTURE. REMARK 225 PROTEIN DATA BANK CONVENTIONS REQUIRE THAT CRYST1 AND REMARK 225 SCALE RECORDS BE INCLUDED, BUT THE VALUES ON THESE REMARK 225 RECORDS ARE MEANINGLESS.
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES: ENGH AND HUBER, 1991 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 VAL A 161 CB - CA - C ANGL. DEV. = 18.3 DEGREES REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 ASN A 195 SER A 196 147.47
REMARK 525 REMARK 525 SOLVENT REMARK 525 THE FOLLOWING SOLVENT MOLECULES LIE FARTHER THAN EXPECTED REMARK 525 FROM THE PROTEIN OR NUCLEIC ACID MOLECULE AND MAY BE REMARK 525 ASSOCIATED WITH A SYMMETRY RELATED MOLECULE (M=MODEL REMARK 525 NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH 216 DISTANCE = 13.23 ANGSTROMS REMARK 525 HOH 217 DISTANCE = 18.00 ANGSTROMS REMARK 525 HOH 218 DISTANCE = 11.86 ANGSTROMS REMARK 525 HOH 220 DISTANCE = 17.08 ANGSTROMS REMARK 525 HOH 225 DISTANCE = 17.40 ANGSTROMS REMARK 525 HOH 227 DISTANCE = 5.53 ANGSTROMS REMARK 525 HOH 230 DISTANCE = 6.24 ANGSTROMS REMARK 525 HOH 232 DISTANCE = 5.24 ANGSTROMS REMARK 525 HOH 234 DISTANCE = 10.45 ANGSTROMS REMARK 525 HOH 235 DISTANCE = 16.48 ANGSTROMS REMARK 525 HOH 237 DISTANCE = 5.29 ANGSTROMS REMARK 525 HOH 238 DISTANCE = 8.02 ANGSTROMS REMARK 525 HOH 242 DISTANCE = 14.36 ANGSTROMS REMARK 525 HOH 243 DISTANCE = 5.09 ANGSTROMS REMARK 525 HOH 246 DISTANCE = 5.19 ANGSTROMS REMARK 525 HOH 248 DISTANCE = 13.02 ANGSTROMS REMARK 525 HOH 250 DISTANCE = 11.38 ANGSTROMS REMARK 525 HOH 251 DISTANCE = 17.61 ANGSTROMS REMARK 525 HOH 252 DISTANCE = 11.11 ANGSTROMS REMARK 525 HOH 253 DISTANCE = 14.61 ANGSTROMS REMARK 525 HOH 254 DISTANCE = 16.91 ANGSTROMS REMARK 525 HOH 255 DISTANCE = 15.42 ANGSTROMS REMARK 525 HOH 256 DISTANCE = 14.60 ANGSTROMS REMARK 525 HOH 260 DISTANCE = 13.63 ANGSTROMS REMARK 525 HOH 261 DISTANCE = 15.74 ANGSTROMS REMARK 525 HOH 262 DISTANCE = 12.65 ANGSTROMS REMARK 525 HOH 264 DISTANCE = 12.96 ANGSTROMS REMARK 525 HOH 265 DISTANCE = 23.16 ANGSTROMS REMARK 525 HOH 266 DISTANCE = 22.51 ANGSTROMS REMARK 525 HOH 267 DISTANCE = 14.95 ANGSTROMS REMARK 525 HOH 268 DISTANCE = 15.11 ANGSTROMS REMARK 525 HOH 269 DISTANCE = 14.16 ANGSTROMS REMARK 525 HOH 270 DISTANCE = 21.38 ANGSTROMS REMARK 525 HOH 271 DISTANCE = 22.12 ANGSTROMS REMARK 525 HOH 272 DISTANCE = 22.37 ANGSTROMS REMARK 525 HOH 274 DISTANCE = 12.67 ANGSTROMS REMARK 525 HOH 276 DISTANCE = 8.50 ANGSTROMS REMARK 525 HOH 283 DISTANCE = 12.78 ANGSTROMS REMARK 525 HOH 291 DISTANCE = 20.40 ANGSTROMS REMARK 525 HOH 292 DISTANCE = 22.68 ANGSTROMS REMARK 525 HOH 293 DISTANCE = 23.95 ANGSTROMS REMARK 525 HOH 294 DISTANCE = 19.35 ANGSTROMS REMARK 525 HOH 296 DISTANCE = 23.74 ANGSTROMS REMARK 525 HOH 297 DISTANCE = 22.79 ANGSTROMS REMARK 525 HOH 298 DISTANCE = 7.68 ANGSTROMS REMARK 525 HOH 299 DISTANCE = 5.82 ANGSTROMS REMARK 525 HOH 300 DISTANCE = 23.03 ANGSTROMS REMARK 525 HOH 301 DISTANCE = 8.83 ANGSTROMS REMARK 525 HOH 303 DISTANCE = 10.32 ANGSTROMS REMARK 525 HOH 304 DISTANCE = 9.70 ANGSTROMS REMARK 525 HOH 305 DISTANCE = 9.04 ANGSTROMS REMARK 525 HOH 306 DISTANCE = 11.42 ANGSTROMS REMARK 525 HOH 308 DISTANCE = 17.97 ANGSTROMS REMARK 525 HOH 309 DISTANCE = 13.07 ANGSTROMS REMARK 525 HOH 310 DISTANCE = 5.89 ANGSTROMS REMARK 525 HOH 313 DISTANCE = 14.69 ANGSTROMS REMARK 525 HOH 315 DISTANCE = 13.46 ANGSTROMS REMARK 525 HOH 316 DISTANCE = 7.45 ANGSTROMS REMARK 525 HOH 317 DISTANCE = 7.71 ANGSTROMS REMARK 525 HOH 318 DISTANCE = 17.27 ANGSTROMS REMARK 525 HOH 332 DISTANCE = 14.33 ANGSTROMS REMARK 525 HOH 333 DISTANCE = 9.44 ANGSTROMS REMARK 525 HOH 334 DISTANCE = 11.93 ANGSTROMS REMARK 525 HOH 335 DISTANCE = 12.74 ANGSTROMS REMARK 525 HOH 336 DISTANCE = 15.94 ANGSTROMS REMARK 525 HOH 337 DISTANCE = 11.33 ANGSTROMS REMARK 525 HOH 338 DISTANCE = 12.46 ANGSTROMS REMARK 525 HOH 339 DISTANCE = 11.54 ANGSTROMS REMARK 525 HOH 340 DISTANCE = 11.27 ANGSTROMS REMARK 525 HOH 341 DISTANCE = 13.63 ANGSTROMS REMARK 525 HOH 342 DISTANCE = 12.12 ANGSTROMS REMARK 525 HOH 343 DISTANCE = 13.88 ANGSTROMS REMARK 525 HOH 344 DISTANCE = 14.32 ANGSTROMS REMARK 525 HOH 345 DISTANCE = 17.10 ANGSTROMS REMARK 525 HOH 347 DISTANCE = 19.19 ANGSTROMS REMARK 525 HOH 348 DISTANCE = 9.00 ANGSTROMS REMARK 525 HOH 349 DISTANCE = 8.71 ANGSTROMS REMARK 525 HOH 350 DISTANCE = 12.87 ANGSTROMS REMARK 525 HOH 352 DISTANCE = 9.92 ANGSTROMS REMARK 525 HOH 353 DISTANCE = 8.72 ANGSTROMS REMARK 525 HOH 354 DISTANCE = 8.98 ANGSTROMS REMARK 525 HOH 355 DISTANCE = 12.35 ANGSTROMS REMARK 525 HOH 356 DISTANCE = 12.25 ANGSTROMS REMARK 525 HOH 358 DISTANCE = 7.22 ANGSTROMS REMARK 525 HOH 359 DISTANCE = 15.99 ANGSTROMS REMARK 525 HOH 360 DISTANCE = 13.25 ANGSTROMS REMARK 525 HOH 361 DISTANCE = 15.60 ANGSTROMS REMARK 525 HOH 362 DISTANCE = 8.51 ANGSTROMS REMARK 525 HOH 363 DISTANCE = 9.85 ANGSTROMS REMARK 525 HOH 365 DISTANCE = 17.24 ANGSTROMS REMARK 525 HOH 369 DISTANCE = 16.32 ANGSTROMS REMARK 525 HOH 371 DISTANCE = 13.10 ANGSTROMS REMARK 525 HOH 377 DISTANCE = 10.07 ANGSTROMS REMARK 525 HOH 378 DISTANCE = 15.30 ANGSTROMS REMARK 525 HOH 379 DISTANCE = 12.22 ANGSTROMS REMARK 525 HOH 381 DISTANCE = 12.45 ANGSTROMS REMARK 525 HOH 390 DISTANCE = 16.00 ANGSTROMS REMARK 525 HOH 392 DISTANCE = 5.19 ANGSTROMS REMARK 525 HOH 393 DISTANCE = 16.54 ANGSTROMS REMARK 525 HOH 394 DISTANCE = 17.93 ANGSTROMS REMARK 525 HOH 396 DISTANCE = 5.08 ANGSTROMS REMARK 525 HOH 397 DISTANCE = 6.48 ANGSTROMS REMARK 525 HOH 398 DISTANCE = 20.98 ANGSTROMS REMARK 525 HOH 399 DISTANCE = 18.96 ANGSTROMS REMARK 525 HOH 400 DISTANCE = 27.54 ANGSTROMS REMARK 525 HOH 403 DISTANCE = 14.29 ANGSTROMS REMARK 525 HOH 405 DISTANCE = 13.21 ANGSTROMS REMARK 525 HOH 406 DISTANCE = 22.36 ANGSTROMS REMARK 525 HOH 407 DISTANCE = 21.84 ANGSTROMS REMARK 525 HOH 408 DISTANCE = 17.01 ANGSTROMS REMARK 525 HOH 413 DISTANCE = 9.95 ANGSTROMS REMARK 525 HOH 414 DISTANCE = 8.89 ANGSTROMS REMARK 525 HOH 416 DISTANCE = 10.13 ANGSTROMS REMARK 525 HOH 417 DISTANCE = 9.75 ANGSTROMS REMARK 525 HOH 418 DISTANCE = 6.61 ANGSTROMS
REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1PPP RELATED DB: PDB REMARK 900 PAPAIN COMPLEX WITH E64-C
DBREF 1EFF A 1 212 UNP P00784 PAPA_CARPA 134 345
SEQADV 1EFF GLN A 47 UNP P00784 GLU 180 CONFLICT SEQADV 1EFF GLN A 118 UNP P00784 GLU 251 CONFLICT SEQADV 1EFF GLN A 135 UNP P00784 GLU 268 CONFLICT
SEQRES 1 A 212 ILE PRO GLU TYR VAL ASP TRP ARG GLN LYS GLY ALA VAL SEQRES 2 A 212 THR PRO VAL LYS ASN GLN GLY SER CYS GLY SER CYS TRP SEQRES 3 A 212 ALA PHE SER ALA VAL VAL THR ILE GLU GLY ILE ILE LYS SEQRES 4 A 212 ILE ARG THR GLY ASN LEU ASN GLN TYR SER GLU GLN GLU SEQRES 5 A 212 LEU LEU ASP CYS ASP ARG ARG SER TYR GLY CYS ASN GLY SEQRES 6 A 212 GLY TYR PRO TRP SER ALA LEU GLN LEU VAL ALA GLN TYR SEQRES 7 A 212 GLY ILE HIS TYR ARG ASN THR TYR PRO TYR GLU GLY VAL SEQRES 8 A 212 GLN ARG TYR CYS ARG SER ARG GLU LYS GLY PRO TYR ALA SEQRES 9 A 212 ALA LYS THR ASP GLY VAL ARG GLN VAL GLN PRO TYR ASN SEQRES 10 A 212 GLN GLY ALA LEU LEU TYR SER ILE ALA ASN GLN PRO VAL SEQRES 11 A 212 SER VAL VAL LEU GLN ALA ALA GLY LYS ASP PHE GLN LEU SEQRES 12 A 212 TYR ARG GLY GLY ILE PHE VAL GLY PRO CYS GLY ASN LYS SEQRES 13 A 212 VAL ASP HIS ALA VAL ALA ALA VAL GLY TYR GLY PRO ASN SEQRES 14 A 212 TYR ILE LEU ILE LYS ASN SER TRP GLY THR GLY TRP GLY SEQRES 15 A 212 GLU ASN GLY TYR ILE ARG ILE LYS ARG GLY THR GLY ASN SEQRES 16 A 212 SER TYR GLY VAL CYS GLY LEU TYR THR SER SER PHE TYR SEQRES 17 A 212 PRO VAL LYS ASN
FTNOTE 1 CIS PROLINE - PRO 152
HET TYL A 213 19 HET MOH 214 6
HETNAM TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) HETNAM MOH METHANOL
FORMUL 2 TYL C8 H9 N O2 FORMUL 3 MOH C H4 O FORMUL 4 HOH *205(H2 O1)
HELIX 1 1 ARG A 8 GLY A 11 5 4 HELIX 2 2 SER A 24 GLY A 43 1 20 HELIX 3 3 GLN A 51 ASP A 57 1 7 HELIX 4 4 TYR A 67 ALA A 76 1 10 HELIX 5 5 CYS A 95 GLU A 99 5 5 HELIX 6 6 ASN A 117 GLN A 128 1 12
SHEET 1 A 5 VAL A 5 ASP A 6 0 SHEET 2 A 5 ALA A 162 GLY A 167 -1 N TYR A 166 O VAL A 5 SHEET 3 A 5 TYR A 170 LYS A 174 -1 O TYR A 170 N GLY A 167 SHEET 4 A 5 TYR A 186 LYS A 190 -1 O ILE A 187 N ILE A 173 SHEET 5 A 5 ILE A 148 PHE A 149 1 N PHE A 149 O ARG A 188 SHEET 1 B 4 VAL A 110 VAL A 113 0 SHEET 2 B 4 SER A 206 PRO A 209 -1 O SER A 206 N VAL A 113 SHEET 3 B 4 SER A 131 LEU A 134 -1 N SER A 131 O PHE A 207 SHEET 4 B 4 HIS A 159 ALA A 160 -1 N HIS A 159 O LEU A 134
SSBOND 1 CYS A 22 CYS A 63 SSBOND 2 CYS A 56 CYS A 95 SSBOND 3 CYS A 153 CYS A 200
LINK C3 TYL A 213 SG CYS A 25 LINK SG CYS A 22 SG CYS A 63 LINK SG CYS A 56 SG CYS A 95 LINK SG CYS A 153 SG CYS A 200
CISPEP 1 GLY A 151 PRO A 152 0 -2.89
CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.023057 0.000000 0.000000 0.00000
SCALE2 0.000000 0.009771 0.000000 0.00000
SCALE3 0.000000 0.000000 0.020020 0.00000